Download by
Scanning QR Code
No Stock Yet
No Data
Icosavax upgraded to Outperform at Evercore on 'competitive' RSV vaccine data
Evercore ISI analyst Josh Schimmer upgraded Icosavax (ICVX) to Outperform from In Line with a price target of $18, up from $10. While "at first glance," it may appear that Icosavax's Respiratory Syncy
GSK Selects Target the Future Grant Recipient in Innovation Challenge Supporting Multiple Myeloma Community
Business Wire 29-Jun-2022 8:00 AMInaugural grant awarded to the HealthTree Foundation, a pioneering non-profit organization whose proposal will address disparities in care in multiple myeloma GSK plc
Global Systemic Lupus Erythematosus (SLE) Market Report 2022-2026: Featuring Pfizer, AstraZeneca, GlaxoSmithKline and Others
Dublin, June 29, 2022 (GLOBE NEWSWIRE) -- The "Global Systemic Lupus Erythematosus (SLE) Market: Analysis By Product Type, By Route of Administration, By End User, By Region Size and Trends with Impact of COVID-19 and forecast up to 2026" report has be
VBI Vaccines boasts of new follow-up data for hepatitis B vaccine over GSK rival
VBI Vaccines (NASDAQ:VBIV) said that its 3-antigen hepatitis B (HBV) vaccine was more effective than GlaxoSmithKline's (GSK) Engerix-B, a single-antigen vaccine, based on phase 3, long-term follow-up
Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK
Ideaya Biosciences Inc (NASDAQ:IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase domain of DNA Polymerase Theta. Ideaya
New Board of Directors at Data Dynamics: Agam Upadhyay, Global CTO from GSK (Formerly GlaxoSmithKline)
TEANECK, N.J., June 28, 2022 /PRNewswire/ -- Data Dynamics, the leader in Unified Unstructured Data Management, today announced the addition of Agam Upadhyay to its Board of Directors. Agam currentl
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Japan's Ministry of Health, Labour and Welfare Accepts Shingrix Regulatory Submission to Prevent Shingles in at-risk Adults Aged 18 Years and Older
GSK plc (NYSE:GSK) today announced the submission of a regulatory application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for th
Ideaya Biosciences selects Pol Theta Helicase development candidate
Ideaya Biosciences (IDYA) announced selection of a potential first-in-class Pol Theta Helicase development candidate, or DC. The Pol Theta Helicase DC is a potential first-in-class small molecule inhi
GlaxoSmithKline Files for Expanded Use of Shingrix Shingles Vaccine in Japan
06:17 AM EDT, 06/28/2022 (MT Newswires) -- GlaxoSmithKline (GSK) said Tuesday that it has filed a regulatory submission to the Japanese Ministry of Health, Labor and Welfare for its Shingrix vaccine t
Loading...
No Stock Yet